Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.

× No keyword cloud information.

21 in total

Review 1. Cardiovascular safety profiles of aromatase inhibitors : a comparative review.

Authors: Jean-Marc Nabholtz; Joseph Gligorov
Journal: Drug Saf Date: 2006 Impact factor: 5.606

Review 2. The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment.

Authors: Mohamed F M Mitwally; Robert F Casper; Michael P Diamond
Journal: Reprod Biol Endocrinol Date: 2005-10-04 Impact factor: 5.211

3. Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug.

Authors: Kun-Eek Kil; Anat Biegon; Yu-Shin Ding; Andre Fischer; Richard A Ferrieri; Sung Won Kim; Deborah Pareto; Michael J Schueller; Joanna S Fowler
Journal: Nucl Med Biol Date: 2009-02 Impact factor: 2.408

Review 4. Anastrozole: in early breast cancer.

Authors: Keri Wellington; Diana M Faulds
Journal: Drugs Date: 2002 Impact factor: 9.546

Review 5. Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects.

Authors: Walter Jonat; Felix Hilpert
Journal: J Cancer Res Clin Oncol Date: 2006-02-01 Impact factor: 4.553

6. Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma.

Authors: J-P Spano; J-C Soria; M Kambouchner; S Piperno-Neuman; F Morin; J-F Morere; A Martin; J-L Breau
Journal: Med Oncol Date: 2003 Impact factor: 3.064

Review 7. The role of aromasin in the hormonal therapy of breast cancer.

Authors: Magdolna Dank
Journal: Pathol Oncol Res Date: 2002 Impact factor: 3.201

8. Environmental phenols and pubertal development in girls.

Authors: Mary S Wolff; Susan L Teitelbaum; Kathleen McGovern; Susan M Pinney; Gayle C Windham; Maida Galvez; Ashley Pajak; Michael Rybak; Antonia M Calafat; Lawrence H Kushi; Frank M Biro
Journal: Environ Int Date: 2015-08-31 Impact factor: 9.621

9. Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial.

Authors: A Barnadas; M Gil; S González; I Tusquets; M Muñoz; A Arcusa; L Prieto; M Margelí-Vila; A Moreno
Journal: Br J Cancer Date: 2009-01-20 Impact factor: 7.640

10. The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer.

Authors: N C Wortham; E Ahamed; S M Nicol; R S Thomas; M Periyasamy; J Jiang; A M Ochocka; S Shousha; L Huson; S E Bray; R C Coombes; S Ali; F V Fuller-Pace
Journal: Oncogene Date: 2009-08-31 Impact factor: 9.867